Nuclear Medicine and Biology
Papers 4070
1 page of 407 pages (4,070 results)
Abstract null null Introduction null Monoclonal antibodies (mAbs) are widely used in nuclear imaging. Radiolabelling with positron emitting radionuclides, typically radiometals, requires the incorporation of a bifunctional chelator for the formation of the radiometal-mAb complex. Additionally, mAbs can be conjugated with small molecules capable to undergo bioorthogonal click reactions in vivo, enabling pre-targeting strategies. The determination of the number of functionalities attached to the m...
#1Motofumi Suzuki (Hokkaido University)H-Index: 6
#2Tatsuki Katayama (Hokkaido University)
Last. Mikako Ogawa (Hokkaido University)H-Index: 44
view all 6 authors...
Abstract null null Introduction null Macrophages play a vital role in the development of atherosclerotic cardiovascular disease. Macrophages are functionally and phenotypically heterogeneous immune cells and commonly exist in two distinct or polarized subsets: pro-inflammatory M1 and anti-inflammatory M2 phenotypes. Previous reports suggest that stimulation of α7 or α4β2 nicotinic acetylcholine receptors (nAChRs) in macrophages leads to an anti-inflammatory response. However, the biological link...
#1Yu-Peng Zhou (Harvard University)H-Index: 11
#2Katarina J. Makaravage (Harvard University)H-Index: 1
Last. Pedro Brugarolas (Harvard University)H-Index: 9
view all 3 authors...
Abstract null null Hydrogen cyanide (HCN) is a versatile synthon for generating carbon‑carbon and carbon-heteroatom bonds. Unlike other one-carbon synthons (i.e., CO, CO2), HCN can function as a nucleophile (as in potassium cyanide, KCN) and an electrophile (as in cyanogen bromide, (CN)Br). The incorporation of the null CN motif into organic molecules generates nitriles, hydantoins and (thio)cyanates, which can be converted to carboxylic acids, aldehydes, amides and amines. Such versatile chemis...
#1Valentin R. Teyssier (UdeM: Université de Montréal)
#2Francois Tournoux (UdeM: Université de Montréal)H-Index: 16
Last. Jean DaSilva (UdeM: Université de Montréal)H-Index: 5
view all 7 authors...
Abstract null null Introduction null The O-[11C]methylated derivatives of the clinically used neprilysin inhibitor (NEPi) sacubitril ([11C]SacOMe, (2R,4S)-ethyl 5-([biphenyl]-4-yl)-4-(4-[11C]methoxy-4-oxobutanamido)-2-methylpentanoate) and LBQ657 ([11C]MeOLBQ, (2R,4S)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid [11C]methyl ester and [11C]LBQOMe, (2R,4S)-5-(biphenyl-4-yl)-4-[(4-[11C]methoxy-4-oxobutanamido)]-2-methylpentanoic acid) were evaluated to determine their pote...
#1Zhengyuan Zhou (Duke University)H-Index: 12
#2Darryl McDougald (Duke University)H-Index: 9
Last. Ganesan Vaidyanathan (Duke University)H-Index: 37
view all 6 authors...
Abstract null null Introduction null Labeling single domain antibody fragments (sdAbs) with 18F is an attractive strategy for immunoPET. Earlier, we developed a residualizing label, N-succinimidyl 3-((4-(4-fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([18F]RL-I), synthesized via a click reaction for labeling sdAbs with 18F, that has attractive features but suffered from modest radiochemical yields and suboptimal hydrophobicity. Herein, we have evaluated the potential ut...
1 CitationsSource
#1Aditya Bansal (Mayo Clinic)H-Index: 11
#2Mukesh K. Pandey (Mayo Clinic)H-Index: 18
Last. Timothy R. DeGrado (Mayo Clinic)H-Index: 44
view all 9 authors...
Abstract null null Introduction null Immunotherapy targeting PD-1/PD-L1 immune checkpoint inhibition (ICI) is efficacious in various solid and hematologic malignancies. However, the response rate to PD-1/PD-L1 therapy is only 15–35%. To obtain optimal clinical response to ICI therapies, a reliable assessment of tumor PD-L1 expression is needed to select appropriate patients, and a non-invasive imaging-based assessment of PD-L1 expression is critically needed. Although radiolabeled PET probes bas...
#1Lorain Geenen (EUR: Erasmus University Rotterdam)
#2Julie Nonnekens (EUR: Erasmus University Rotterdam)H-Index: 11
Last. An AertsH-Index: 13
view all 6 authors...
Peptide receptor radionuclide therapy (PRRT) is used for the treatment of patients with unresectable or metastasized somatostatin receptor type 2 (SSTR2)-expressing gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The radiolabelled somatostatin analogue [177Lu]Lu-DOTA-TATE delivers its radiation dose to SSTR2-overexpressing tumour cells, resulting in selective cell killing during radioactive decay. While tumour control can be achieved in many patients, complete remissions remain rare, c...
#1Sadaf Aghevlian (Stanford University)H-Index: 1
#2Bo Wu (Stanford University)H-Index: 3
Last. Katherine W. Ferrara (Stanford University)H-Index: 73
view all 7 authors...
Abstract Background A novel 64Cu[Cu]-NOTA-aCD40 immunoPET tracer was developed to image a CD40+ pancreatic tumor model in C57BL/6 mice and to study the biodistribution profile of the agonist CD40 (aCD40) monoclonal antibody (mAb) alone or combined with other mAbs. Procedures Copper-64 (64Cu[Cu]) labeled NOTA-aCD40 and NOTA-IgG (10 μg; 7 MBq) were injected intravenously into C57BL/6 mice with subcutaneous mT4 tumors to assess specificity 48 h post injection (p.i.) through positron emission tomogr...
#1Nathalie Heynickx (UGent: Ghent University)
#2Ken Herrmann (UCLA: University of California, Los Angeles)H-Index: 67
Last. An AertsH-Index: 13
view all 5 authors...
Abstract At present, prostate cancer remains the second most occurring cancer in men, in Europe. Treatment efficacy for therapy of advanced metastatic disease, and metastatic castration-resistant prostate cancer in particular is limited. Prostate-specific membrane antigen (PSMA) is a promising therapeutic target in prostate cancer, seeing the high amount of overexpression on prostate cancer cells. Clinical investigation of PSMA-targeted radionuclide therapy has shown good clinical efficacy. Howe...
3 CitationsSource
#1Ines M. Costa ('KCL': King's College London)
#2Jordan Cheng ('KCL': King's College London)
Last. Samantha Y.A. Terry ('KCL': King's College London)H-Index: 13
view all 5 authors...
Abstract In oncology, the holy grail of radiotherapy is specific radiation dose deposition in tumours with minimal healthy tissue toxicity. If used appropriately, injectable, systemic radionuclide therapies could meet these criteria, even for treatment of micrometastases and single circulating tumour cells. The clinical use of α and β- particle-emitting molecular radionuclide therapies is rising, however clinical translation of Auger electron-emitting radionuclides is hampered by uncertainty aro...
Top fields of study
Organic chemistry
In vitro
In vivo